Biotechnology | Disease | FDA
FDA approves Novo Nordisk’s Sogroya® as first and only once-weekly, long-acting growth hormone for three additional pediatric indications
On Feb. 27, 2026, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved three…